Quantifying gastric Helicobacter pylori infection: a comparison of quantitative culture, urease breath testing, and histology.
Although there are several methods to detect Helicobacter pylori infection, there is no simple validated test to quantify the density of infection, which is believed to play a major role in the pathogenesis of H. pylori-associated gastritis and peptic ulceration. The aim of this study was to evaluate and compare noninvasive and invasive tests for assessing the level of H. pylori infection so as to facilitate the development and clinical testing of new antibiotic treatments. Healthy volunteers (n=323) were screened for H. pylori infection by serology and, if positive (n=86), invited to undergo (13)C urea breath testing (UBT) (n=55). An increase of >2.4 parts per thousand (13)CO(2) at 15 min compared to baseline was considered a positive test. Total cumulative urease activity (mumol) at 60 min was also calculated. UBT-positive subjects underwent endoscopy and nine biopsies were obtained from defined sites for quantitative culture and histological grading using the modified Sydney System. A total of 19 subjects were studied, 4 of whom underwent repeat testing. All subjects were positive for H. pylori by serology, UBT, culture, and histology. The increase in (13)CO(2) at 30 min correlated with the total cumulative urease activity at 60 min (r (2)=0.92, P< 0.0001). Bacterial counts (log cfu/biopsy; mean+/-SD) were 3.9+/-0.5, 3.9+/-0.4, and 3.9+/-0.6 at the lesser curve antrum, greater curve antrum, and corpus, respectively. There was no significant correlation between UBT results and bacterial counts at any biopsy site. Nor was there any significant correlation between the histology grading and either the UBT or the bacterial counts at any site. This study indicates that there is little correlation among the three methods used to measure bacterial burden in H. pylori infection. Thus, decrements in bacterial numbers during single-agent therapy cannot be measured reliably by UBT and therefore cannot be used to evaluate the potential efficacy of novel agents to treat gastric H. pylori infection.
Tummala
Sanjeev
S
Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Sheth
Sunil G
SG
Goldsmith
Jeffrey D
JD
Goldar-Najafi
Atoussa
A
Murphy
Christopher K
CK
Osburne
Marcia S
MS
Mullin
Steven
S
Buxton
Debra
D
Wagner
David A
DA
Kelly
Ciarán P
CP
D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D001944:Breath Tests; D002245:Carbon Dioxide / Q000378:metabolism; D015169:Colony Count, Microbial; D004384:Duodenoscopy; D004386:Duodenum / Q000382:microbiology / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015203:Reproducibility of Results; D013270:Stomach / Q000382:microbiology / Q000473:pathology; D013997:Time Factors; D014510:Urease / Q000378:metabolism*
D000907:Antibodies, Bacterial; D002245:Carbon Dioxide; D014510:Urease